本帖最后由 老马 于 2013-3-13 13:43 编辑 + U5 J7 V9 b8 a) v& W3 b, U
; n/ z+ F( e0 v" b: @/ M健择（吉西他滨）+顺铂+阿瓦斯汀
0 |: L; m: X5 R8 l7 m Gemzar +Cisplatin + Avastin
" s- i% ?. p4 j' f; Ohttp://annonc.oxfordjournals.org/content/21/9/1804.full$ {$ u+ A$ E. x* J0 l
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: e: m. I/ \* T5 B0 t) P; N4 PPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. : [7 r& \1 r( ^- ]4 T' D& T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" R6 s1 h* z: ^# V# u! R
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 627)
4 k6 c5 j9 ~3 j! c- \& S& f% {2 I* n
华为网盘附件：( u( U" q# u5 U1 U: i
【华为网盘】ava.JPG' q5 e: K, L/ u& a ^6 J
|
显身卡
